Literature DB >> 8660163

Cytomegalovirus retinitis and viral resistance. Prevalence of resistance at diagnosis, 1994. Cytomegalovirus Retinitis and Viral Resistance Study Group.

D A Jabs1, J P Dunn, C Enger, M Forman, N Bressler, P Charache.   

Abstract

OBJECTIVE: To determine the prevalence of cytomegalovirus (CMV) isolates resistant to ganciclovir sodium or foscarnet sodium at the time of diagnosis of CMV retinitis, prior to the initiation of therapy.
DESIGN: Prospective epidemiologic study.
SETTING: An acquired immunodeficiency syndrome ophthalmology clinic. PATIENTS: Patients with acquired immunodeficiency syndrome and newly diagnosed CMV retinitis. INTERVENTION: Culturing blood and urine samples for CMV and testing of all positive isolates for sensitivity to ganciclovir and foscarnet. MAIN OUTCOME MEASURE: Prevalence of the following: blood culture isolates resistant to ganciclovir (inhibitory concentration 50% [IC50] > 5.5 mumol/L) or foscarnet (IC50 > 400 mumol/L) and urine culture isolates resistant to ganciclovir or foscarnet.
RESULTS: Forty-nine patients were enrolled during a 13-month period. Forty-four patients had blood culture samples that could be evaluated; of these, 66% were positive (59% of patients). Thirty-four patients had urine cultures that were evaluable; of these, 82% were positive (57% of patients). Overall, 78% of patients had either a urine or blood culture sample positive for CMV. No blood culture isolates were resistant to ganciclovir, and only 1 urine culture isolate (2% of patients) was resistant to ganciclovir. Three percent of blood culture isolates and 4% of urine culture isolates (2% and 2% of patients, respectively) were resistant to foscarnet. Overall, 4% of patients had either a blood or urine culture isolate resistant to foscarnet.
CONCLUSION: Resistance to ganciclovir or foscarnet at the time of diagnosis of CMV retinitis is uncommon.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8660163     DOI: 10.1001/archopht.1996.01100140023002

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  12 in total

1.  Limitations of cytomegalovirus testing.

Authors:  J Harmenberg; M Brytting
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

2.  Cytomegalovirus retinitis and the acquired immunodeficiency syndrome--bench to bedside: LXVII Edward Jackson Memorial Lecture.

Authors:  Douglas A Jabs
Journal:  Am J Ophthalmol       Date:  2010-12-18       Impact factor: 5.258

3.  Detection of cytomegalovirus drug resistance mutations by next-generation sequencing.

Authors:  Malaya K Sahoo; Martina I Lefterova; Fumiko Yamamoto; Jesse J Waggoner; Sunwen Chou; Susan P Holmes; Matthew W Anderson; Benjamin A Pinsky
Journal:  J Clin Microbiol       Date:  2013-08-28       Impact factor: 5.948

4.  A novel human cytomegalovirus glycoprotein, gpUS9, which promotes cell-to-cell spread in polarized epithelial cells, colocalizes with the cytoskeletal proteins E-cadherin and F-actin.

Authors:  E Maidji; S Tugizov; G Abenes; T Jones; L Pereira
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

Review 5.  Ganciclovir. A pharmacoeconomic review of its use as intravenous or oral maintenance therapy in the management of cytomegalovirus retinitis in patients with AIDS.

Authors:  C M Perry; R Davis
Journal:  Pharmacoeconomics       Date:  1997-08       Impact factor: 4.981

6.  Comparison of cytomegalovirus loads in plasma and leukocytes of patients with cytomegalovirus retinitis. The Cytomegalovirus Retinitis and Viral Resistance Study Group.

Authors:  D A Jabs; M Forman; C Enger; J B Jackson
Journal:  J Clin Microbiol       Date:  1999-05       Impact factor: 5.948

7.  Incidence of foscarnet resistance and cidofovir resistance in patients treated for cytomegalovirus retinitis. The Cytomegalovirus Retinitis and Viral Resistance Study Group.

Authors:  D A Jabs; C Enger; M Forman; J P Dunn
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

8.  The D-form of a novel heparan binding peptide decreases cytomegalovirus infection in vivo and in vitro.

Authors:  Elisabeth A Pitt; Pranay Dogra; Ravi S Patel; Angela Williams; Jonathan S Wall; Tim E Sparer
Journal:  Antiviral Res       Date:  2016-09-25       Impact factor: 5.970

9.  Mortality associated with resistant cytomegalovirus among patients with cytomegalovirus retinitis and AIDS.

Authors:  Douglas A Jabs; Barbara K Martin; Michael S Forman
Journal:  Ophthalmology       Date:  2009-10-08       Impact factor: 12.079

10.  Detection of ganciclovir resistance in patients with AIDS and cytomegalovirus retinitis: correlation of genotypic methods with viral phenotype and clinical outcome.

Authors:  Douglas A Jabs; Barbara K Martin; Michelle O Ricks; Michael S Forman
Journal:  J Infect Dis       Date:  2006-05-10       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.